000117652 001__ 117652
000117652 005__ 20240319081018.0
000117652 0247_ $$2doi$$a10.3390/cancers14102374
000117652 0248_ $$2sideral$$a128599
000117652 037__ $$aART-2022-128599
000117652 041__ $$aeng
000117652 100__ $$aMorote, Juan
000117652 245__ $$aComparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
000117652 260__ $$c2022
000117652 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117652 5203_ $$aThis study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.
000117652 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666
000117652 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117652 590__ $$a5.2$$b2022
000117652 592__ $$a1.312$$b2022
000117652 591__ $$aONCOLOGY$$b72 / 241 = 0.299$$c2022$$dQ2$$eT1
000117652 593__ $$aOncology$$c2022$$dQ1
000117652 593__ $$aCancer Research$$c2022$$dQ2
000117652 594__ $$a7.4$$b2022
000117652 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117652 700__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, Angel$$uUniversidad de Zaragoza
000117652 700__ $$aTriquell, Marina
000117652 700__ $$aCelma, Anna
000117652 700__ $$aRegis, Lucas
000117652 700__ $$aMast, Richard
000117652 700__ $$ade Torres, Inés M.
000117652 700__ $$aSemidey, María E.
000117652 700__ $$aAbascal, José M.
000117652 700__ $$aServian, Pol
000117652 700__ $$aSantamaría, Anna
000117652 700__ $$aPlanas, Jacques
000117652 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis M.
000117652 700__ $$aTrilla, Enrique
000117652 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología
000117652 773__ $$g14, 10 (2022), 2374 [22 pp.]$$pCancers$$tCancers$$x2072-6694
000117652 8564_ $$s1271900$$uhttps://zaguan.unizar.es/record/117652/files/texto_completo.pdf$$yVersión publicada
000117652 8564_ $$s2853323$$uhttps://zaguan.unizar.es/record/117652/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117652 909CO $$ooai:zaguan.unizar.es:117652$$particulos$$pdriver
000117652 951__ $$a2024-03-18-15:51:35
000117652 980__ $$aARTICLE